Trials / Completed
CompletedNCT02278367
Clinical Evaluation of Flortaucipir F 18
Clinical Evaluation of 18F-AV-1451
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 179 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flortaucipir F18 | IV injection, 370 MBq (10 mCi), up to two doses |
| PROCEDURE | Brain PET scan | positron emission tomography (PET) scan of the brain |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2019-06-26
- Completion
- 2019-06-26
- First posted
- 2014-10-30
- Last updated
- 2020-09-10
- Results posted
- 2020-09-10
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02278367. Inclusion in this directory is not an endorsement.